For instance, a combination of CAR-NK cells targeting mesothelin and the STING agonist cGAMP (cyclic GMP-AMP) showed improved anti-tumour efficacy in a mouse model of pancreatic cancer, indicated by the inhibition of tumour growth and the prolongation of survival, in comparison to either treatment alone [109]. Here, MSLN is linked to familial pancreatic carcinoma.